Related Experiment Video

Updated: Jun 21, 2026

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
07:30

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

Discovery of an inhibitor of insulin-like growth factor 1 receptor activation: implications for cellular potency and

Edgar R Wood1, Lisa Shewchuk, Anne Hassel

  • 1Department of Biological Reagents and Assay Development, Research Triangle Park, GlaxoSmithKline, Inc., NC 27709, United States. erw39216@gsk.com

Biochemical Pharmacology
|August 12, 2009
PubMed

Insights

Researchers discovered a novel purine derivative that selectively targets the non-phosphorylated insulin-like growth factor 1 receptor (IGF-1R) kinase, offering a potential anti-cancer therapy with fewer metabolic side effects than current inhibitors.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Pharmacology

Background:

  • Insulin-like growth factor 1 receptor (IGF-1R) is a key target in anti-cancer therapy due to its role in preventing tumor cell apoptosis.
  • Inhibiting IGF-1R is complicated by its structural similarity to the insulin receptor (IR), leading to potential metabolic side effects.

Purpose of the Study:

  • To identify novel small-molecule inhibitors that selectively target IGF-1R over IR.
  • To explore the potential of targeting the non-phosphorylated state of IGF-1R for improved therapeutic selectivity.

Main Methods:

  • A cell-based assay measuring IGF-1R autophosphorylation was employed for inhibitor screening.
  • Biochemical and structural studies were conducted to characterize the inhibitor's binding mode and selectivity.
  • Comparative analysis of inhibitor potency against activated and non-phosphorylated kinase domains of IGF-1R and IR.

Main Results:

  • A potent purine derivative was identified with selectivity for IGF-1R over IR.
  • The compound demonstrated weak inhibition of the activated IGF-1R tyrosine kinase domain.
  • Preferential binding of the compound to the ATP site of non-phosphorylated IGF-1R compared to phosphorylated IGF-1R was observed.

Conclusions:

  • The identified purine derivative exhibits a novel binding mode targeting the non-phosphorylated IGF-1R.
  • This selective targeting strategy holds promise for developing anti-cancer therapies with reduced metabolic liabilities.
  • Further investigation into the therapeutic potential of non-phosphorylated IGF-1R inhibitors is warranted.

More Related Videos

An In Ovo Model for Testing Insulin-mimetic Compounds06:09

An In Ovo Model for Testing Insulin-mimetic Compounds

Published on: April 23, 2018

Related Concept Videos

Insulin: The Receptor and Signaling Pathways01:28

Insulin: The Receptor and Signaling Pathways

Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but this inhibition is released...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...